Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-02

Study Completion Date

2022-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353

Glioblastoma Newly Diagnosed Glioblastoma

COMPLETED PHASE1

Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

NCT03477110

Glioblastoma

COMPLETED EARLY_PHASE1

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

NCT04471844

Glioblastoma Multiforme

ACTIVE_NOT_RECRUITING NA

Preoperative Preradiotherapy TTFields

NCT06136611

Glioblastoma

NOT_YET_RECRUITING NA

Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data

NCT06346821

Glioblastoma Multiforme

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.

The expected toxicity is skin related, and patients will be followed closely with weekly skin and neurological examinations during radiation therapy and for 8 weeks afterwards to capture any delayed toxicity as they begin adjuvant therapy per routine treatment. As long as study treatment is tolerated and their conditions remain stable, patients will continue the treatment for up to 24 months.

Prior to enrollment, an exploratory analysis of radiation dosimetry will be performed by phantom modeling incorporating the Optune arrays. The study incorporates three stages of recruitment to confirm the safety of combining tumor treating fields therapy with concurrent chemoradiation: a safety lead-in cohort of the first 6 patients enrolled, a second safety lead-in cohort of 9 patients, and an expansion cohort with 15 additional patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Cancer of Brain Glioblastoma Multiforme Brain Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

The study is an open-label pilot study. Following surgery, eligible patients will start tumor treating fields therapy with the Optune device less than 2 weeks prior to radiation and temozolomide given at a dose and schedule conforming to routine treatment.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.

Group Type EXPERIMENTAL

Tumor Treating Fields

Intervention Type DEVICE

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.

Temozolomide

Intervention Type DRUG

Patients will be given temozolomide according to routine treatment dosing and schedule.

Radiation Therapy

Intervention Type RADIATION

Patients will be given radiation therapy according to routine treatment dosing and schedule.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumor Treating Fields

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.

Intervention Type DEVICE

Temozolomide

Patients will be given temozolomide according to routine treatment dosing and schedule.

Intervention Type DRUG

Radiation Therapy

Patients will be given radiation therapy according to routine treatment dosing and schedule.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Optune Novocure Temodar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. GBM or Gliosarcoma by histology
2. MGMT methylation status and IDH mutation status must be assessed at the study site or patient's referral center. MGMT status will be used for stratification purposes but will not exclude patients from this study if they are either methylated, unmethylated, or indeterminate, or in process at the time of enrollment. Similarly, subjects with tumors that are IDH mutated or wild type are both eligible.
3. Supratentorial location
4. Maximum safe resection (including patients who can only safely be biopsied)
5. 22 years of age or older
6. Estimated survival of at least 12 weeks
7. KPS 70% or greater at time of entry to study
8. Patient provided written informed consent, or provided by a legally authorized representative
9. Willingness to comply with all procedures, including visits or evaluations, imaging, laboratory tests and rescue measures
10. Acceptable method of birth control (see appendix)
11. Have had a contrast-enhanced brain MRI after tumor resection procedure. If biopsy alone performed, cranial CT may be used in place of MRI, only if the patient had a preoperative MRI scan within 14 days of the biopsy.
12. The following time period must have elapsed prior to study enrollment: 3-6 weeks (21-42 days) from time of definitive surgery or 2-4 weeks (14-28 days) from the time of biopsy, for those who were only able to safely have a biopsy and not full resection.

Exclusion Criteria

1. Craniotomy or stereotactic biopsy wound dehiscence or infection
2. Known by history to be HIV positive or to have an AIDS-related illness, active Hepatitis B, or active Hepatitis C (testing not required)
3. Presence of skull defects (bullets, metal fragments, missing bone)
4. Patients with implanted electronic medical devices (including but not limited to: pacemaker, vagal nerve stimulator, or pain stimulator)
5. Prior invasive malignancy, unless disease free for 3 or more years, with the exception of basal cell carcinoma, cervical carcinoma in situ, or melanoma in situ
6. Recurrent malignant gliomas or higher grade gliomas transformed from previous low grade (II) glioma
7. Patients with any current Primary brain stem or spinal cord tumor
8. Prior use of temozolomide
9. Prior treatment with Avastin
10. Individuals requiring \>8mg of dexamethasone per day within 7 days prior to Day 1 (high dose steroid taper following craniotomy with \>8mg of dexamethasone is allowed during the screening period, but subjects must taper down to 8mg or less of dexamethasone (or bioequivalent) within 7 days prior to Day 1).
11. Clinically significant lab abnormalities at screening showing bone marrow, hepatic, and renal dysfunction:

* Thrombocytopenia (platelet count \< 100 x 103/μL)
* Neutropenia (absolute neutrophil count \< 1.5 x 103/μL)
* Significant liver function impairment - AST or ALT \> 3 times the upper limit of normal
* Total bilirubin \> upper limit of normal
* Significant renal impairment (serum creatinine \> 1.7 mg/dL)
12. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting) at screening
13. Inability to swallow pills
14. Clinically significant or unstable comorbid medical condition, per investigator discretion (for example, active or uncontrolled infection requiring systemic therapy, including known HIV or hepatitis B or C virus)
15. Known current alcohol or drug abuse, per investigator discretion. Prior history of substance abuse is permissible if subject has been sober for the past 3 years.
16. Any clinically significant psychiatric condition that would prohibit patient willingness or ability to successfully complete study procedures, per investigator discretion
17. Patients with an allergy to or an inability to have gadolinium contrast dye administered with MRI
18. Patients with aneurysm clips or implanted metal objects in the brain
19. Patients with significant skin breakdown on the scalp
20. Patients who cannot receive standard of care radiation therapy and can only receive hypofractionated radiation due to age and poor performance status , per investigator discretion

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No